Business Description

Aktis Oncology Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, that develops targeted radiopharmaceuticals for the treatment of solid tumors. The company utilizes a proprietary miniprotein radioconjugate platform designed to deliver alpha-emitting radioisotopes directly to cancer cells while limiting exposure to healthy tissue.

Everything on Aktis Oncology, Inc.

Revenue (FY2025) $6M
YoY growth +336.9%
Operating margin -1149.5%
Direction Expanding
Gross margin 100.0%
Net margin -980.9%

Leadership & board

View leadership ↗
Matthew Roden, PhD — President, Chief Executive Officer and Director View full profile ↗ Kyle D. Kuvalanka — Chief Financial Officer View full profile ↗ Akos Czibere, MD, PhD — Chief Medical Officer View full profile ↗ Paul L. Feldman, PhD — Chief Scientific Officer View full profile ↗ Shulamit Ron-Bigger, PhD — Chief Operating Officer View full profile ↗ Tyler Benedum, PhD — Chief Technical Officer View full profile ↗ Todd Foley, MBA — Chair of the Board of Directors View full profile ↗ Ken Herrmann, MD — Director View full profile ↗ Helen S. Kim, MBA — Director View full profile ↗ Oleg Nodelman — Director View full profile ↗ Lloyd M. Segal, MBA — Director View full profile ↗ Michael A. Sherman, MBA — Director View full profile ↗ Mary Thistle — Director View full profile ↗

Share Repurchase Program

Total authorized
None. Aktis Oncology does not have a share repurchase or buyback program.
Remaining (Fiscal year ended December 31, 2025)
Not applicable.
Latest FY repurchased
No shares were repurchased under any buyback program; the company has never paid dividends and has no repurchase authorization.

Named Competitors

Abdera TherapeuticsActinium PharmaceuticalsAlpha9 OncologyArtbioBayerConvergent TherapeuticsFusion PharmaceuticalsJohnson & JohnsonMariana OncologyPerspective TherapeuticsPOINT Biopharma GlobalRadioMedixRadionetics OncologyRayzeBioTelix PharmaceuticalsLantheus HoldingsNovartis +5 more

Recent SEC Filings

2026-08-13 Reported quarterly results View filing ↗
2026-05-11 Reported quarterly results View filing ↗
2026-04-16 Leadership change (directors/officers) (+1 more) View filing ↗
2026-03-30 Reported quarterly results View filing ↗
2026-01-12 Amended charter/bylaws View filing ↗

More Companies

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.